Loading...
•
Mar 31, 2021
Accuray Q3 2021 Earnings Report
Accuray's financial performance reflected positive momentum despite COVID-19 headwinds, with system revenue conversion in China and FDA clearance for ClearRT Helical kVCT Imaging.
Key Takeaways
Accuray reported a net revenue of $102.6 million for the third quarter of fiscal year 2021, which includes $24.9 million of system revenue in China. The company's GAAP operating income was $4.4 million, but they experienced a net loss of $0.4 million. Gross orders totaled $87.4 million, and the ending backlog increased by 7 percent from the previous year to $610.8 million.
Net revenue reached $102.6 million, including $24.9 million from system revenue in China.
Gross orders amounted to $87.4 million, with an ending backlog of $610.8 million, a 7% increase year-over-year.
GAAP operating income was $4.4 million, while the GAAP net loss was $0.4 million.
FDA clearance was received for ClearRT™ Helical kVCT Imaging for the Radixact® System.
Accuray
Accuray
Accuray Revenue by Segment
Revenue by Segment
Products Revenue
CapyFin.comServices Revenue
CapyFin.com Forward Guidance
Accuray refrained from providing financial guidance for fiscal year 2021 due to the uncertainty surrounding the impact of the COVID-19 pandemic on the global economy and the healthcare industry.
Revenue & Expenses
Visualization of income flow from segment revenue to net income